Camzyos (mavacamten) - BMS
Co-Administration of Mavacamten and Tacrolimus in a Renal Transplant Recipient With Obstructive Hypertrophic Cardiomyopathy. (PubMed, JACC Case Rep) - Oct 10, 2026 - "Low-dose mavacamten and tacrolimus coadministration is feasible. However, rigorous tacrolimus therapeutic drug monitoring remains essential, especially during mavacamten dose escalation." 
Journal • Cardiomyopathy • Cardiovascular • Genetic Disorders • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Transplantation • CYP3A4
http://www.ncbi.nlm.nih.gov/pubmed/42853175
 
Andrew Willeford; Arman Faravardeh; Jorge Silva Enciso; Quan M Bui
 
Oct 10, 2026
 
Prev Next